RxDoctor Payments Data

German Ferrer, MD

Family Medicine · Coquille, ORNPI 1003391046

Payments from drug & device makers

$337in general payments, 2019–2025

Across 15 payments — averaging $22.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$97
  • Novo Nordisk$51
  • AbbVie$46
  • Amgen$37
  • GSK$31
  • Madrigal Pharmaceuticals$26
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$337100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis4$97
Novo Nordisk2$51
AbbVie2$46
Amgen2$37
GSK1$31
Madrigal Pharmaceuticals1$26
Biocryst US Sales Co., LLC1$21
Pfizer1$20
Microline Surgical Inc1$8

How this compares

$337 in reported general payments places this provider in the 75th percentile of 1,221 family medicine providers in Oregon.

See all family medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$15,903
Medicare patients
52
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$42,147
OzempicSemaglutide36$34,032
XareltoRivaroxaban16$20,184
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,595
Breo ElliptaFluticasone/Vilanterol11$4,551
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates57$3,767
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$3,114
Potassium Chloride35$2,053
Gabapentin86$2,044
Albuterol Sulfate HfaAlbuterol Sulfate55$1,971
Quetiapine Fumarate12$1,532
Tamsulosin Hcl44$1,400
Levothyroxine Sodium109$1,368
Atorvastatin Calcium147$1,306
Metoprolol Succinate75$1,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$42,14743 claims
Novo NordiskOzempic$51$34,03236 claims
GSKTrelegy Ellipta, Breo Ellipta$31$13,14623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,221 family medicine providers in Oregon.

Other family medicine in Coquille

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →